",n.parentNode.insertBefore(a,n)};if(!!document.cookie.match(/cookieConsent=true/))window.gaf(); ',{'forceSSL':true});


     (2 March 2021)  Kalos prepares to list in Frankfurt via reverse merger or traditional IPO.

ValiRx PLC Agreement with Kalos Therapeutics:

    (10 November 2020) ValiRx (AIM: VAL) a clinical stage drug development company, announces today that it has entered into an agreement with Kalos Therapeutics (Kalos), a US-based private biotechnology company, to evaluate its peptide KTH222 as a drug candidate for treating patients with ovarian cancer.

Kalos Therapeutics Announces Early Positive Data Against SARS-CoV-2 For COVID-19 Program:

    (August 21, 2020) Kalos Therapeutics today announced positive preclinical efficacy results from a series of Kalos peptides for the treatment of COVID-19.

Kalos therapeutics announces important progress in therapeutic peptide for cancer program:

    (May 30, 2020 ) Kalos therapeutics is developing a novel, small peptide with activity against human pancreatic cancer

© 2020 Kalos Therapeutics. All Rights Reserved.

This website makes use of cookies. Please see our privacy policy for details.